Follow us on:

Linkedin Facebook

September 18, 2025

Broker Ratings

Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyzing the 81% Potential Upside in Biotechnology

Broker Ratings

Alumis Inc. (ALMS) Stock Analysis: A Biotech with a Potential 360% Upside

Broker Ratings

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Biotech with a 46% Upside Potential

Broker Ratings

CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a Potential 197.93% Upside in Biotechnology

Broker Ratings

Viemed Healthcare, Inc. (VMD) Stock Analysis: A Potential 99% Upside in the Medical Device Sector

Broker Ratings

Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring a Potential 196% Upside in the Biotech Sector

Broker Ratings

Cartesian Therapeutics, Inc. (RNAC) Stock Report: Unpacking a 298% Potential Upside in Biotechnology

Broker Ratings

Cytek Biosciences, Inc. (CTKB) Stock Analysis: Unpacking a 30.74% Potential Upside for Investors

Broker Ratings

Cidara Therapeutics (CDTX) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena

Broker Ratings

Chevron Corporation (CVX) Investor Outlook: Analyzing a 4.27% Dividend Yield Amidst Market Dynamics

Broker Ratings

aTyr Pharma, Inc. (ATYR) Stock Analysis: Navigating a Potential 393.90% Upside in Biotech

Real Estate Credit Investments Limited

Real Estate Credit Investments maintains quarterly 3p dividend for 8 years (LON:RECI)

Real Estate Credit Investments has declared a first interim dividend of 3.0 pence per Ordinary Share for the year ending 31 March 2026, payable on 17 October 2025 to shareholders on the register as of 26 September 2025...
Broker Ratings

Abeona Therapeutics Inc. (ABEO) Stock Analysis: Eyeing a 263% Upside with Biotech Innovations

Broker Ratings

Aurora Cannabis Inc. (ACB) Stock Analysis: Exploring a 26.99% Upside Potential Amidst Revenue Growth

Broker Ratings

Aura Biosciences, Inc. (AURA) Stock Analysis: Eyeing a 247.54% Potential Upside with Innovative Oncology Solutions

Broker Ratings

Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a 306% Potential Upside in the Biotechnology Sector

Broker Ratings

ClearPoint Neuro Inc. (CLPT) Stock Analysis: Exploring a 172% Potential Upside in the Medical Devices Sector

Broker Ratings

Spok Holdings, Inc. (SPOK) Stock Analysis: A 20% Upside Potential with Strong Dividend Yield

Broker Ratings

UroGen Pharma Ltd. (URGN) Stock Analysis: Navigating an 86% Potential Upside in the Biotech Sector

Broker Ratings

Olema Pharmaceuticals (OLMA) Investor Outlook: Exploring a 222% Potential Upside

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

September 18, 2025

Broker Ratings

Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyzing the 81% Potential Upside in Biotechnology

Broker Ratings

Alumis Inc. (ALMS) Stock Analysis: A Biotech with a Potential 360% Upside

Broker Ratings

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Biotech with a 46% Upside Potential

Broker Ratings

CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a Potential 197.93% Upside in Biotechnology

Broker Ratings

Viemed Healthcare, Inc. (VMD) Stock Analysis: A Potential 99% Upside in the Medical Device Sector

Broker Ratings

Gossamer Bio, Inc. (GOSS) Stock Analysis: Exploring a Potential 196% Upside in the Biotech Sector

Broker Ratings

Cartesian Therapeutics, Inc. (RNAC) Stock Report: Unpacking a 298% Potential Upside in Biotechnology

Broker Ratings

Cytek Biosciences, Inc. (CTKB) Stock Analysis: Unpacking a 30.74% Potential Upside for Investors

Broker Ratings

Cidara Therapeutics (CDTX) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena

Broker Ratings

Chevron Corporation (CVX) Investor Outlook: Analyzing a 4.27% Dividend Yield Amidst Market Dynamics

Broker Ratings

aTyr Pharma, Inc. (ATYR) Stock Analysis: Navigating a Potential 393.90% Upside in Biotech

Real Estate Credit Investments Limited

Real Estate Credit Investments maintains quarterly 3p dividend for 8 years (LON:RECI)

Real Estate Credit Investments has declared a first interim dividend of 3.0 pence per Ordinary Share for the year ending 31 March 2026, payable on 17 October 2025 to shareholders on the register as of 26 September 2025...
Broker Ratings

Abeona Therapeutics Inc. (ABEO) Stock Analysis: Eyeing a 263% Upside with Biotech Innovations

Broker Ratings

Aurora Cannabis Inc. (ACB) Stock Analysis: Exploring a 26.99% Upside Potential Amidst Revenue Growth

Broker Ratings

Aura Biosciences, Inc. (AURA) Stock Analysis: Eyeing a 247.54% Potential Upside with Innovative Oncology Solutions

Broker Ratings

Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a 306% Potential Upside in the Biotechnology Sector

Broker Ratings

ClearPoint Neuro Inc. (CLPT) Stock Analysis: Exploring a 172% Potential Upside in the Medical Devices Sector

Broker Ratings

Spok Holdings, Inc. (SPOK) Stock Analysis: A 20% Upside Potential with Strong Dividend Yield

Broker Ratings

UroGen Pharma Ltd. (URGN) Stock Analysis: Navigating an 86% Potential Upside in the Biotech Sector

Broker Ratings

Olema Pharmaceuticals (OLMA) Investor Outlook: Exploring a 222% Potential Upside

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

September 18, 2025

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple